<DOC>
	<DOCNO>NCT01588795</DOCNO>
	<brief_summary>The DERENEDIAB study proof-of-concept , multi-center , prospective , open , randomize , control study effectiveness renal denervation addition standardize medical treatment compare medical treatment alone diabetic subject diabetic nephropathy resistant proteinuria . Bilateral renal denervation perform use Symplicity Catheter - percutaneous system delivers radiofrequency ( RF ) energy luminal surface renal artery .</brief_summary>
	<brief_title>Renal Denervation Diabetic Nephropathy</brief_title>
	<detailed_description>The DERENEDIAB study proof-of-concept multi-center , prospective , open , randomize , control study effectiveness renal denervation addition standardize medical treatment compare medical treatment alone diabetic subject diabetic nephropathy resistant proteinuria . Bilateral renal denervation perform use Symplicity Catheter - percutaneous system delivers radiofrequency ( RF ) energy luminal surface renal artery .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Type 2 diabetes mellitus male female patient Individual &gt; 18 ≤ 75 year old Diabetic nephropathy ( pathological examination , diagnosis base association history diabetes , diabetic retinopathy hematuria ) Proteinuria/creatininuria ratio &gt; 0.1 g/mmol last 8 week Under stable medication regimen include least 2 month full tolerate dos al least 1 RAAS blocker ( ACEI , renin inhibitor , ARB ) diuretic 2 functional kidney size ≥ 90 mm ; eGFR &gt; 20 mL/min/1.73m² ( MDRD formula Suitable aortorenal vascular anatomy compatible endovascular denervation procedure ; Informed consent sign Health insurance policy active Patients estimate glomerular filtration rate ( eGFR ) less 20 mL/min/1.73 m2 Patients unable sign inform consent , understand protocol , live far specialize center Nondiabetic renal disease Patients severe hypertension ( grade 3 ESH classification ) Kaliemia ≥ 6mmol/L History nephrogenic fibrosisinduced MRI contrast medium Patient single function kidney Patient contrast medium allergy Patient implantable device incompatible low frequency wave delivery Patient contraindication antiproteinuric standardized medication regimen Patient transient fix cerebral ischemia within 3 month inclusion Patient myocardial infarction , unstable angina pectoris , coronary bypass percutaneous angioplasty within 3 month inclusion Patient asthma chronic obstructive pulmonary disease contraindication betablockers medication Patient type 1 diabetes mellitus Uncontrolled type 2 diabetes mellitus ( Hb1Ac &gt; 10 % ) Patient malignancy within 5 past year Patient medical surgical condition could worsen risk study , accord investigator ; Patient chronic alcohol consumption Patient atrial fibrillation and/or brachial circumference ≥ 42cm Patient pregnant , nurse planning pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>renal denervation</keyword>
	<keyword>nephroprotection</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Renal injury</keyword>
	<keyword>End stage renal disease</keyword>
</DOC>